Bis-pyridylpyridones as melanin-concentrating hormone receptor antagonists

A compound of Formula I,

• or a pharmaceutically acceptable salt thereof wherein:
• R1 and R2 independently are selected from the group consisting of:
• hydrogen, C1-6alkyl, C3-6cycloalkyl, acyl, aryl, and heteroaryl;
• R3 is selected from the group consisting of hydrogen, C1-7alkyl, C3-6cycloalkyl, —C(O)NRaRb, —C(O)Ra, —SO2Ra, and —C(O)ORa;
• or R2 and R3 together with the nitrogen to which R3 is attached form a heterocycloalkyl, and said heterocycloalkyl is optionally substituted with one, two, or three Rc groups;
• R4 is selected from the group consisting of:
• hydrogen, C1-6alkyl, heterocycloalkyl optionally substituted with one to three groups selected from:
• H, F, Cl, CF3, C1-6alkyl, C4-6cycloalkyl, —(CH2)0-2-heterocycloalkyl, hydroxyl, alkoxy, acyl, acylamino, amide, oxo, methyl, amino, alkyl amino, or CN;
• or R3 and R4 together with the nitrogen to which they are attached form a heterocycle, and said heterocycle is optionally substituted with one or two Rd groups;
• R5 is H, F, Cl, C1-3alkyl, cyclopropyl, C1-3alkoxy, amino, C1-3alkylamino, oxo, or CN;
• Ra is selected from the group consisting of:
• hydrogen, C1-6alkyl, C3-6cycloalkyl, aryl, and heteroaryl;
• Rb is selected from the group consisting of:
• hydrogen, and C1-6alkyl;
• Rc is H, F, Cl, C1-6alkyl, C3-6cycloalkyl, alkoxy, amino, alkylamino, oxo, or CN;
• Rd is H, F, Cl, C1-6alkyl, C3-6cycloalkyl, alkoxy, amino, alkylamino, hydroxyl, oxo, or CN, —C(O)NRaRb, —C(O)Ra, —SO2Ra, —N(Ra)C(O)ORa or —C(O)ORa;
• X is (CH2)m;
• Y is (CH2)p;
• m is 0-2;
• n is 0-3;
• p is 1-2;
• with the proviso that R3 is not —SO2H or —COOH.